Business Wire

CRESTBRIDGE

25.7.2022 16:48:05 CEST | Business Wire | Press release

Share
Crestbridge Appoints New Luxembourg Country Head, as the Business Advances Its Leading Position Locally and Internationally

Crestbridge, the agile alternative for private equity and real estate administration solutions, today announced the appointment of Anne Catherine Grave as Country Head of Luxembourg.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005497/en/

Based in Luxembourg, Anne Catherine will be responsible for leading the business in the region and building on its reputation as a leading service provider for fund managers.

Since establishing a presence in Luxembourg 11 years ago, Crestbridge has continued its commitment to quality, evolving its service proposition in line with the jurisdiction’s own exponential growth. This is testament to Crestbridge’s popularity amongst fund managers, driven by the firm's expertise in management company services, private equity, real estate, private debt and venture capital.

Anne Catherine’s appointment adds further weight to Crestbridge’s highly experienced Luxembourg team, who provides global, comprehensive support to fund managers. This includes managing the administrative, accounting, reporting, residency and governance needs of a broad range of fund structures throughout their lifecycles.

Prior to joining Crestbridge, Anne Catherine was the Partner in charge of Corporate Secretarial Services in Deloitte in Luxembourg. She has over 20 years' experience in Private Equity and Real Estate sectors.

Anne Catherine gained her extensive experience as part of the Management/Executive Committees of Arendt Services in Luxembourg, as well as in her position as Executive Director of Bedell (which became Ocorian), a Luxembourg Trust & Fund business of a Jersey Group. In both positions, she served as board members of various regulated and non-regulated clients’ entities. Anne Catherine’s area of activities included the compliance, corporate, governance, tax, internal control and risk management functions. She started her career as tax advisor in Ernst & Young in Luxembourg and New York, before transitioning into a Senior Tax Lawyer position at a Luxembourg Law Firm, Arendt.

Anne Catherine holds masters’ degrees in economics and in International & European law, a post-graduate diplomas in Political Sciences as well as in International Business Law. She is also qualified as a Certified International Control Specialist and has a qualification in risk management. She was a Chartered Accountant in Luxembourg and a qualified attorney in France and Luxembourg. Anne Catherine was the Chair of the ILA Company Secretary and Governance Officer Committee for 4 years. She remains an active member of such committee and is a speaker for the ILA Company Secretary and Governance Officer Committee certification.

Michael Johnson, Group Head of Institutional Services, Crestbridge, said:

“I'm delighted to welcome Anne Catherine to the team and am delighted that Crestbridge continues to be a business where top, global talent comes to work and thrive. Anne Catherine will be leading some of the best talent available in the region, people who are focused on delivering exceptional service and innovative solutions to our global client base. Anne Catherine offers the team not only considerable technical expertise but vast knowledge, having worked with some of the biggest names in the industry. I look forward to her playing a vital role in leading and driving forward our Luxembourg and international business.”

-ENDS-

Notes to editors

  • We are a leading global administration, management & corporate governance solutions business.
  • We provide a broad range of outsourced fiduciary, administrative, accounting, and compliance services globally – our expertise spans services, asset classes, and jurisdictions. Since 1998, we have been putting our insight and experience to work for clients who include leading corporations, sovereign wealth funds, investor groups, asset managers, and ultra-high net worth families.
  • Crestbridge employs over 500+ people and has nine international offices: Bahrain, Cayman, Ireland, Jersey, London, Luxembourg, New Jersey, New York, and Southampton.
  • We are regulated in our locations (see here for more details)

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye